PolyPeptide Group: Provisional interim result of the public tender offer of Samsung Biologics Co., Ltd.

Media Release – ad hoc announcement pursuant to Art. 53 LR

Provisional interim result of the public tender offer of Samsung Biologics Co., Ltd.

Baar, Switzerland, 13 October 2026 – Samsung Biologics Co., Ltd. ("Samsung Biologics"), through its direct subsidiary Samsung Peptide AG ("Samsung Peptide"), today published the provisional interim result of its public tender offer (the "Offer") for all publicly held registered shares of PolyPeptide Group AG ("PolyPeptide") (SIX: PPGN).

The main offer period of the Offer ended on 12 October 2026, at 4:00 p.m. Swiss time. According to the provisional interim result as published by Samsung Peptide,

• the participation of Samsung Peptide and the persons acting in concert with Samsung Peptide amounts to 29,123,892 PolyPeptide shares in aggregate, corresponding to 87.92% of the issued share capital and voting rights of PolyPeptide (participation rate); and
• 29,014,418 PolyPeptide shares were tendered into the Offer until the end of the main offer period of the Offer, corresponding to 87.59% of the issued share capital and voting rights of PolyPeptide and 87.88% of all PolyPeptide shares to which the Offer relates (success rate).

The interim result that has been published today by Samsung Peptide is provisional and is available at https://samsungbiologics.com/offer. The definitive interim result is expected to be published on 16 October 2026. The provisional and the definitive end result of the Offer will be published after the end of the additional acceptance period (see below).

According to the provisional interim result as published by Samsung Peptide,

• subject to confirmation of the preliminary numbers in the definitive interim result, the offer condition pursuant to section B.7.1(a) (Minimum Acceptance Rate) of the offer prospectus of Samsung Peptide dated 31 August 2026 (the "Offer Prospectus") has been satisfied; and
• in addition, the offer condition pursuant to section B.7.1(d) (No Material Adverse Effect) of the Offer Prospectus has also been satisfied.

The Offer remains subject to customary offer conditions, including the receipt of regulatory approvals in certain jurisdictions as well as the removal of the transfer restrictions and voting limitations from PolyPeptide’s articles of association and the election of the persons nominated by Samsung Biologics to the board of directors of PolyPeptide by resolution of an extraordinary general meeting of PolyPeptide. PolyPeptide has invited for an extraordinary general meeting to be held on 26 October 2026 to resolve on these matters.

According to the provisional interim result as published by Samsung Peptide, if the Offer is declared successful (zustande gekommen) in the definitive notice of the interim result, the additional acceptance period of ten (10) trading days for the subsequent acceptance of the Offer will commence on 19 October 2026 and end on 30 October 2026, 4:00 p.m. Swiss time, in accordance with section B.6 (Additional Acceptance Period) of the Offer Prospectus.

Contact

PolyPeptide Group AG Strategic Marketing and Corporate Communications Laura Rosso mediateam@polypeptide.com T: +41 43 502 0580 PolyPeptide Group AG Finance / Investor Relations Tim Brandl investorrelations@polypeptide.com T: +41 43 502 0580   

About PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries ("PolyPeptide") is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-pre-clinical to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide's shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com.

@PolyPeptide -- follow us on LinkedIn

About Samsung Peptide and Samsung Biologics

Samsung Peptide is a direct subsidiary of Samsung Biologics. Samsung Biologics and PolyPeptide have concluded a transaction agreement on 17 July 2026 regarding the Offer. Samsung Peptide is acting as the formal offeror of the Offer. Samsung Biologics (KRX: 207940.KS) is a leading Contract Development & Manufacturing Organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II in Korea, and 60,000 from the acquisition of a manufacturing facility in Rockville, Maryland, U.S., Samsung Biologics holds total global manufacturing capacity of 845,000 liters. Samsung Biologics has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities. Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity. Samsung Biologics' global manufacturing and commercial network spans Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. Samsung Biologics is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health. For more information, please visit https://samsungbiologics.com. 

Legal Notice and Disclaimer

No Offer / Offer Restrictions

The information in this media release is for informational purposes only. It does not constitute, or form part of, any offer or invitation to purchase, sell, exchange or issue, or any solicitation of an offer to sell, purchase, exchange or subscribe to, any registered shares or other securities of PolyPeptide or any other person, nor shall it form the basis of, or be relied upon in connection with, any contract in relation thereto. This media release is not part of Samsung Peptide's publication of the provisional interim result of the Offer or any other publication, communication or other documentation of Samsung Peptide or Samsung Biologics relating to the Offer, including without limitation the Offer Prospectus (the "Offer Documentation”). Terms and conditions of the Offer have been published by Samsung Peptide and Samsung Biologics in the Offer Documentation. Shareholders of PolyPeptide are urged to read the Offer Documentation, which is available at https://samsungbiologics.com/offer.

This announcement is not for publication, release or distribution in any country or jurisdiction in which it would be considered unlawful or otherwise violate any applicable laws or regulations, or which would require Samsung Peptide or Samsung Biologics to change or amend the terms or conditions of the Offer in any way, to make an additional filing with any governmental, regulatory or other authority or take additional action in relation to the Offer. Full Offer restrictions can be found in Samsung Peptide's Offer Prospectus at https://samsungbiologics.com/offer.

Forward-looking Information and Statements

This media release has been prepared by PolyPeptide and includes forward-looking information and statements concerning the outlook for the Group’s business. These statements are based on current expectations, estimates and projections about the factors that may affect the Group's future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as ‘expects’, ‘believes’, ‘estimates’, ‘targets’, ‘plans’, ‘projects’, ‘outlook’ or similar expressions. There are numerous risks, uncertainties and other factors, many of which are beyond PolyPeptide’s control, that could cause the group’s actual results to differ materially from the forward-looking information and statements made in this media release and that could affect the group’s ability to achieve its stated targets. Although PolyPeptide believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.

Except as otherwise required by law, PolyPeptide disclaims any intention or obligation to update any forward-looking statements as a result of developments.